Vigeo Therapeutics will present New Clinical and Immune Profiling Data from Ph I/II Expansion study in GBM Patients in ASCO Poster Oral Session

/PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new data from its Phase I/II...

Related Keywords

Chicago ,Illinois ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Davidm Peereboom ,Jing Watnick ,David Peereboom ,American Society Of Clinical Oncology ,Cleveland Clinic ,American Society ,Clinical Oncology ,Saturday June ,Central Nervous System ,Vigeo Therapeutics ,